A Phase I/II trial of vaccine therapy of HIV-1 infected individuals with 50-500 CD4 cells/mm3. This study closed to further enrollment on -1-95 after an interim analysis was completed. The vaccine was shown to be well tolerated but to have little effect on lymphocyte proliferation.
Showing the most recent 10 out of 1065 publications